As a result, the pharmaceutical industry continues to rely on animal studies to generate PK data on compound absorption, clearance, and systemic exposure. These studies, often conducted in dogs and non-human primates, are costly, low throughput, and offer poor translatability to human outcomes. The Company's standardized discovery and development workflows de-risk pipelines with earlier, more confident decision-making, helping to reduce reliance on animal testing in pharmaceutical research. The Innovate UK-funded project will explore the development and validation of a standardized workflow for human-relevant PK studies, building on CN Bio's established dual-organ PhysioMimix Gut/Liver MPS. Dr Yassen Abbas, Biology Group Leader, CN Bio, said: "We're proud to have been selected for this project by Innovate UK, an exciting opportunity to advance the UK Government target to reduce dedicated PK studies using dogs or non-human primates by 35%.